Riluzole for Degenerative Cervical Myelopathy
JAMA Network Open · 21.06.2024 · 7 (6) · e2415643
DOI: 10.1001/jamanetworkopen.2024.15643 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JAMA Network Open, online erschienen am 21.06.2024. Verfasst von Michael G Fehlings und 23 weiteren Autor:innen. Beteiligte Einrichtung: Division of Neurosurgery, Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Riluzole, Cervical Vertebrae. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance The modified Japanese Orthopaedic Association (mJOA) scale is the most common scale used to represent outcomes of degenerative cervical myelopathy (DCM); however, it lacks consideration for neck pain scores and neglects the multidimensional aspect of recovery after surgery.
Objective
To use a global statistical approach that incorporates assessments of multiple outcomes to reassess the efficacy of riluzole in patients undergoing spinal surgery for DCM. Design, Setting, and Participants This was a secondary analysis of prespecified secondary end points within the Efficacy of Riluzole in Surgical Treatment for Cervical Spondylotic Myelopathy (CSM-PROTECT) trial, a multicenter, double-blind, phase 3 randomized clinical trial conducted from January 2012 to May 2017. Adult surgical patients with DCM with moderate to severe myelopathy (mJOA scale score of 8-14) were randomized to receive either riluzole or placebo. The present study was conducted from July to December 2023.
Intervention
Riluzole (50 mg twice daily) or placebo for a total of 6 weeks, including 2 weeks prior to surgery and 4 weeks following surgery. Main Outcomes and Measures The primary outcome measure was a difference in clinical improvement from baseline to 1-year follow-up, assessed using a global statistical test (GST). The 36-Item Short Form Health Survey Physical Component Score (SF-36 PCS), arm and neck pain numeric rating scale (NRS) scores, American Spinal Injury Association (ASIA) motor score, and Nurick grade were combined into a single summary statistic known as the global treatment effect (GTE).
Results
Overall, 290 patients (riluzole group, 141; placebo group, 149; mean [SD] age, 59 [10.1] years; 161 [56%] male) were included. Riluzole showed a significantly higher probability of global improvement compared with placebo at 1-year follow-up (GTE, 0.08; 95% CI, 0.00-0.16; P = .02). A similar favorable global response was seen at 35 days and 6 months (GTE for both, 0.07; 95% CI, −0.01 to 0.15; P = .04), although the results were not statistically significant. Riluzole-treated patients had at least a 54% likelihood of achieving better outcomes at 1 year compared with the placebo group. The ASIA motor score and neck and arm pain NRS combination at 1 year provided the best-fit parsimonious model for detecting a benefit of riluzole (GTE, 0.11; 95% CI, 0.02-0.16; P = .007). Conclusions and Relevance In this secondary analysis of the CSM-PROTECT trial using a global outcome technique, riluzole was associated with improved clinical outcomes in patients with DCM. The GST offered probability-based results capable of representing diverse outcome scales and should be considered in future studies assessing spine surgery outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Neurosurgery, Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada.
- Division of Neurosurgery and Spine Program, Department of Surgery, University of Toronto, Toronto, Ontario, Canada.
- Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada.
- Division of Orthopaedic Surgery, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
- Department of Neurological Surgery, Ohio State University, Columbus.
- Department of Neurosurgery, University of Virginia, Charlottesville.
Zitieren
APA
Fehlings, M. G., Pedro, K. M., Alvi, M. A., Badhiwala, J. H., Ahn, H., Farhadi, H. F., Shaffrey, C. I., Nassr, A., Mummaneni, P., Arnold, P. M., Jacobs, W. B., Riew, K. D., Kelly, M., Brodke, D. S., Vaccaro, A. R., Hilibrand, A. S., Wilson, J., Harrop, J. S., Yoon, S. T., …, & Huang, P. (2024). Riluzole for Degenerative Cervical Myelopathy. JAMA Network Open, 7(6), e2415643. https://doi.org/10.1001/jamanetworkopen.2024.15643
Vancouver
Fehlings MG, Pedro KM, Alvi MA, Badhiwala JH, Ahn H, Farhadi HF, et al. Riluzole for Degenerative Cervical Myelopathy. JAMA Network Open. 2024;7(6):e2415643. doi:10.1001/jamanetworkopen.2024.15643
BibTeX
@article{Fehlings2024,
author = {Fehlings, Michael G and Pedro, Karlo M and Alvi, Mohammed Ali and Badhiwala, Jetan H and Ahn, Henry and Farhadi, H Francis and Shaffrey, Christopher I and Nassr, Ahmad and Mummaneni, Praveen and Arnold, Paul M and Jacobs, W Bradley and Riew, K Daniel and Kelly, Michael and Brodke, Darrel S and Vaccaro, Alexander R and Hilibrand, Alan S and Wilson, Jason and Harrop, James S and Yoon, S Tim and Kim, Kee D and Fourney, Daryl R and Santaguida, Carlo and Massicotte, Eric M and Huang, Peng},
title = {Riluzole for Degenerative Cervical Myelopathy},
journal = {JAMA Network Open},
year = {2024},
volume = {7},
number = {6},
pages = {e2415643},
doi = {10.1001/jamanetworkopen.2024.15643}
}
EUVIMED